Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune …
Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2025
NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2025 PROXY FORM (CLICK TO VIEW AND DOWNLOAD) ANNUAL REPORT AND CONSOLIDATED …
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical …
Meet Mark Kubik, Head of Business Development – Oncology
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on Thursday, May 29th at 2:20 PM ET BOSTON and LONDON – May 22, 2025 – Akari Therapeutics, Plc …
